Biogen Stock Price and Value Analysis

Should you buy Biogen stock? (NasdaqGS:BIIB). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
  • This company is very stable.
  • This company has stable growth.
  • This stock looks overpriced.
  • This company is making money at a modest rate.
  • This company pays no dividend.

Inside the BIIB Numbers

BIIB Price
(Biogen stock price per share)
$283.44
[?] BIIB Fair Price
(based on intrinsic value)
$248.28
[?] BIIB Safety Price (based on a variable margin of safety) $198.62
[?] PE Ratio versus Sector 27% lower than other Healthcare stocks
[?] PE Ratio versus Industry 41% lower than other Unknown stocks
[?] Cash Yield 8.83%
[?] Free Cash Flow Jitter 20%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,498,811 shares shorted. With 143,562,200 shares available for purchase and an average trading volume over the past 10 trading days of 1,284,570, it would take at least 1.945 days for all of the short holders to cover their shorts.

Is Biogen Stock on Sale?

We believe that Biogen may be worth examining further. It's making money, which is a very positive sign. Is it on sale?

Biogen looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.

Should You Buy BIIB Stock?

Does Biogen have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.